Please assess the completion status of the following clinical trial:

Trial Title: The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CKD patients with type 2 diabetes mellitus~* Patients whose estimated GFR levels are eligible for this study~* Patients being treated with stable dose of angiotensin converting enzyme (ACE) inhibitors and/or angiotensin II receptor blocker (ARB) etc.~Exclusion Criteria:~* Patients with type 1 diabetes mellitus~* Patients with known non-diabetic renal disease~* Patients with a history of renal transplantation~* Patients with mean systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 90 mmHg~* Patients with Hemoglobin A1c \> 10%~* Patients with cardiovascular disease specified in the study protocol etc.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- bardoxolone methyl (Type: EXPERIMENTAL): bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules, once daily for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).